6,247 results match your criteria rate orr


Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial.

Ann Oncol 2021 Jul 19. Epub 2021 Jul 19.

Service de Dermatologie et Cancérologie Cutanée, Aix-Marseille University, Marseille, France.

Background: Pembrolizumab demonstrated clinically meaningful and durable antitumor activity with a manageable safety profile in recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).

Patients And Methods: KEYNOTE-629 was a global, open-label, nonrandomized, phase 2 trial of patients with locally advanced (LA) or R/M cSCC conducted at 59 centers. Eligible patients received intravenous pembrolizumab 200 mg every three weeks for up to 35 cycles. Read More

View Article and Full-Text PDF

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.

J Clin Oncol 2021 Jul 22:JCO2003555. Epub 2021 Jul 22.

Memorial Sloan Kettering Cancer Center, New York, NY.

Purpose: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348).

Patients And Methods: Patients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks). Read More

View Article and Full-Text PDF

Transforming C Molecules into Polyhedral Carbon Micro-Nano Shells for Electrochemically Producing HO in Neutral Electrolytes.

ACS Appl Mater Interfaces 2021 Jul 22. Epub 2021 Jul 22.

CAS Key Laboratory of Design and Assembly of Functional Nanostructures, and Fujian Key Laboratory of Nanomaterials, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian 350002, China.

The electrochemical production of hydrogen peroxide (HO) via the two-electron oxygen reduction reaction (ORR) can realize the customer-oriented onsite synthesis of HO in a green and sustainable method. The ongoing challenge that needs to be solved is the fabrication of robust electrocatalysts of excellent performance. In this work, C was selected as a precursor due to its uniform structure and abundant pentagon rings. Read More

View Article and Full-Text PDF

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.

Clin Transl Oncol 2021 Jul 22. Epub 2021 Jul 22.

Medical Oncology Department, Hospital de La Santa Creu I Sant Pau, Sant Quintí, 89, 08041, Barcelona, Spain.

Background: Anti-angiogenic agents are reported to exert clinical activity in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). We evaluated the outcomes of the combination of docetaxel plus nintedanib in refractory NSCLC patients harboring EGFR mutations.

Methods: We retrospectively analyzed 19 patients with advanced EGFR-mutant NSCLC who had progressed to EGFR tyrosine kinase inhibitors (TKI) and platinum-based chemotherapy receiving docetaxel and nintedanib at 14 Spanish institutions from January 2013 to December 2019. Read More

View Article and Full-Text PDF

Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.

Thorac Cancer 2021 Jul 21. Epub 2021 Jul 21.

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China.

Background: Programmed cell death ligand-1 (PD-L1) is a useful biomarker in non-small cell lung cancer (NSCLC) patients who would probably benefit from immunotherapy. In most patients with advanced stage NSCLC, only small biopsy specimens were available for the evaluation of PD-L1 expression. In this study, we evaluated the feasibility and reliability of PD-L1 testing on small biopsy samples. Read More

View Article and Full-Text PDF

Low-Dose Radiotherapy Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas.

Front Oncol 2021 5;11:716002. Epub 2021 Jul 5.

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States.

Purpose: Radiation therapy (RT) with doses ranging from 24 Gray (Gy) to 40 Gy is a proven treatment modality for indolent orbital adnexal lymphoma (IOAL), but recently the use of low dose RT (LDRT, defined as 2 Gy x 2 fractions) has become a notable alternative. However, limited data exists comparing outcomes following LDRT to moderate-dose RT (MDRT, RT dose 4 - 36 Gy). We present a single institution retrospective analysis comparing outcomes of patients with IOALs following LDRT or MDRT. Read More

View Article and Full-Text PDF

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.

Ther Adv Med Oncol 2021 9;13:17588359211030210. Epub 2021 Jul 9.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong'an Road, Shanghai, 200032, P.R. China.

Background: Eribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after ⩾2 lines of chemotherapy. The aim of this study was to determine the efficacy and safety profile of eribulin and explore potential predictive factors for the efficacy of eribulin among Chinese women with metastatic breast cancer (MBC) in real-world practice.

Patients And Methods: A total of 272 consecutive MBC patients who were treated with eribulin between November 2019 and October 2020 in 9 institutions nationwide were included in this study. Read More

View Article and Full-Text PDF

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).

Clin Med Insights Oncol 2021 8;15:11795549211021667. Epub 2021 Jul 8.

Vita Salute San Raffaele University and Department of Urology, IRCCS San Raffaele Hospital, Milano, Italy.

Background: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine the outcomes of mUC patients after progression to ICI, especially when receiving chemotherapy. Read More

View Article and Full-Text PDF

Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report.

Onco Targets Ther 2021 15;14:4201-4209. Epub 2021 Jul 15.

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, People's Republic of China.

Background: Doublet or triplet chemotherapy plus or minus targeted drugs can achieve a high objective response rate (ORR) and are currently considered to be the backbone of conventional therapy for liver metastatic colorectal cancer (mCRC). However, current biomarkers (such as UGT1A1 and DPYD) are limited to the prediction of toxicity and there are no effective biomarkers to predict chemotherapy response. Therefore, personalized cancer chemotherapy underpinned by genomic alterations in mCRC has received increasing attention. Read More

View Article and Full-Text PDF

Lenvatinib: Established and Promising Drug for the Treatment of Advanced Hepatocellular Carcinoma.

Expert Rev Clin Pharmacol 2021 Jul 22. Epub 2021 Jul 22.

Department of Health Sciences, University of Florence, 50139, Florence, Italy.

Introduction: : The evolving therapeutic landscape of advanced hepatocellular carcinoma (HCC) includes the increasing implementation of target-therapy and immunotherapy. Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma. Its approval has changed the scenario of first-line therapies for advanced HCC, where just sorafenib proved clinical efficacy for over a decade. Read More

View Article and Full-Text PDF

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting.

Cancer Manag Res 2021 12;13:5613-5621. Epub 2021 Jul 12.

Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.

Purpose: We report the efficacy and safety of venetoclax plus decitabine-based treatment in heavily pre-treated relapsed or refractory acute myeloid leukaemia (RR-AML) in a real-world setting.

Patients And Methods: There were 22 patients in this study and the median age was 47.5 (12-84) years old, including 11 males and 11 females. Read More

View Article and Full-Text PDF

Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma.

Urol Oncol 2021 Jul 17. Epub 2021 Jul 17.

Department of Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.

Objectives: The use of antibiotics alters gut microbiota and has been reported to impact outcomes in immune checkpoint inhibitor (ICI) treatment in various types of cancer. We investigated the impact of antibiotics on patients with metastatic urothelial carcinoma (mUC) treated with pembrolizumab.

Materials And Methods: The data of 67 patients with chemotherapy-resistant mUC who were treated with pembrolizumab were retrospectively evaluated. Read More

View Article and Full-Text PDF

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.

BMC Med 2021 Jul 21;19(1):154. Epub 2021 Jul 21.

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: Immune checkpoint inhibitor (ICI) therapy elicits durable antitumor responses in patients with many types of cancer. Genomic mutations may be used to predict the clinical benefits of ICI therapy. NOTCH homolog-4 (NOTCH4) is frequently mutated in several cancer types, but its role in immunotherapy is still unclear. Read More

View Article and Full-Text PDF

First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.

Oncology 2021 Jul 20:1-10. Epub 2021 Jul 20.

Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.

Objectives: The aim of the study was to examine the effectiveness of a modified-short hydration gemcitabine and cisplatin (m-shGC) regimen for patients with metastatic urothelial carcinoma (mUC) and to assess the efficacy of a geriatric nutritional risk index (GNRI) with regard to prognosis.

Patients And Methods: From January 2016 to July 2020, 68 patients with mUC underwent first-line m-shGC therapy with 70 mg/m2 cisplatin and 1,000 mg/m2 gemcitabine (days 1, 8, and 15), with 2,050 mL fluid replaced on the first day of each 28-day cycle. Prior to the start of treatment, the serum neutrophil-to-lymphocyte ratio (NLR), and levels of albumin and C-reactive protein (CRP) in serum, as well as body heights and weights were measured. Read More

View Article and Full-Text PDF

Outcomes with CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Transplant Cell Ther 2021 Jul 17. Epub 2021 Jul 17.

Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS. Electronic address:

Background: Poor graft function (PGF) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) characterized by multilineage cytopenia in the absence of mixed donor chimerism (<95% donor), relapse, or severe graft-vs-host disease (GVHD). We present a systemic review and meta-analysis aimed to assess the outcomes with CD34-selected stem cell boost (SCB) for PGF in adult allo-HSCT patients.

Methods: We screened a total of 1753 records identified from 4 databases (PubMed, Embase, Cochrane, and Clinical trials. Read More

View Article and Full-Text PDF

Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion.

Ann Transl Med 2021 Jun;9(12):1014

Department of Medical Oncology, Shanghai Pulmonary Hospital &Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.

Background: Alectinib and crizotinib have been approved as first-line therapies for advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene fusion. However, the therapeutic efficacy and side effects are still largely unknown of patients who switched to next-generation ALK tyrosine kinase inhibitors (ALK-TKIs), such as alectinib, after experiencing no disease progression with initial crizotinib treatment.

Methods: This prospective real-world study enrolled patients who were treated with alectinib after experiencing no disease progression with initial crizotinib treatment. Read More

View Article and Full-Text PDF

Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.

Front Med (Lausanne) 2021 30;8:616380. Epub 2021 Jun 30.

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Previous studies have evaluated the efficacy (OS, overall survival; PFS, progression-free survival; ORR, objective response rate) and adverse events of bevacizumab combined with platinum-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer (NSCLC) compared with chemotherapy alone. However, the results were inconsistent. We conducted a comprehensive search of PubMed, EMBASE, and Cochrane Library for potentially eligible articles. Read More

View Article and Full-Text PDF

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL.

Front Oncol 2021 30;11:640166. Epub 2021 Jun 30.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Chimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the overall response rate (ORR) of which in the B-NHL patients is much lower compared to the patients with r/r B acute lymphoblastic leukemia (B-ALL). We previously confirmed that sequential infusions of CD20 and CD22 CAR-T cells significantly improved the prognosis of the B-NHL patients, while some advanced patients still progressed to death during these CAR-T cell treatments. In this study, we showed that timely sequential administration of the second CAR-T cells could enhance expansion of prior CAR-T cells with stronger tumor-killing capacity and . Read More

View Article and Full-Text PDF

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.

Front Immunol 2021 30;12:673636. Epub 2021 Jun 30.

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China.

Graft-versus-host disease (GVHD), especially steroid-refractory GVHD, remains a life-threatening complication after hematopoietic stem cell transplantation (HSCT). The effect of the JAK1/2 kinase inhibitor ruxolitinib on treating steroid-refractory acute GVHD has been verified by the REACH1/2 study; however, its safety and efficacy in patients with steroid-refractory chronic GVHD (SR-cGVHD) remain unclear. In this retrospective study, 70 patients received ruxolitinib as a salvage therapy for SR-cGVHD. Read More

View Article and Full-Text PDF

Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador.

Vaccine 2021 Jul 15. Epub 2021 Jul 15.

Independent Consultant, Geneva, Switzerland. Electronic address:

Detection and surveillance of vaccine safety hazards is a public health staple. In the post-marketing phase, when vaccines are used in mass, it is crucial to monitor potential signals of adverse reactions that may have been missed in the pre-marketing phase. We analysed spontaneous reports of drug adverse events in El Salvador to assess a potential safety signal related to an increase in febrile seizures following the pentavalent (diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae Type B) vaccine in 2019. Read More

View Article and Full-Text PDF

A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.

BMC Cancer 2021 Jul 18;21(1):830. Epub 2021 Jul 18.

Third Division of Department of General Surgery of Changzheng Hospital affiliated with Naval Military Medical University, Fengyang Road, Shanghai, 200003, China.

Background: Although various clinical trials and real-life studies have tried to explore the value of nab-paclitaxel mono-chemotherapy for metastatic breast cancer (MBC), the safety and efficacy of nab-paclitaxel remain unclear which need to be systematically evaluated.

Methods: Electronic searches for prospective clinical trials evaluating nab-paclitaxel monotherapy for MBC were performed. Requisite data were extracted, integrated and analysed from the included studies according to the different study designs using systematic review and meta-analysis. Read More

View Article and Full-Text PDF

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.

J Eur Acad Dermatol Venereol 2021 Jul 17. Epub 2021 Jul 17.

Kyowa Kirin International, Buckinghamshire, UK.

Background: Mogamulizumab was compared with vorinostat in the phase 3 MAVORIC trial (NCT01728805) in 372 patients with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS) who had failed ≥1 prior systemic therapy. Mogamulizumab significantly prolonged progression-free survival (PFS), with a superior objective response rate (ORR) versus vorinostat.

Objectives: This post hoc analysis was performed to evaluate the effect of baseline blood tumour burden on patient response to mogamulizumab. Read More

View Article and Full-Text PDF

Bortezomib- Based Therapy For Newly Diagnosed Multiple Myeloma Patients Ineligible For Autologous Stem Cell Transplantation: Czech Registry Data.

Eur J Haematol 2021 Jul 17. Epub 2021 Jul 17.

Department of Hematooncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

Objectives: This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible.

Patients And Methods: We analyzed data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group (CMG) to provide real-world evidence of outcome for 794 newly diagnosed MM transplant ineligible patients. The most frequently used regimen was VCd (bortezomib-cyclophosphamide-dexamethasone) (47. Read More

View Article and Full-Text PDF

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.

J Hematol Oncol 2021 Jul 16;14(1):111. Epub 2021 Jul 16.

Karyopharm Therapeutics, Newton, USA.

Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median duration of response (DOR) of 9. Read More

View Article and Full-Text PDF

A Comparison of Surgical Complications in Patients Undergoing Delayed versus Staged Tissue-Expander and Free-Flap Breast Reconstruction.

Plast Reconstr Surg 2021 Jul 16. Epub 2021 Jul 16.

From the Division of Plastic, Maxillofacial, and Oral Surgery, Department of Surgery, Duke University Health System; and Duke Cancer Biostatistics, Duke University Medical Center.

Background: Patients undergoing mastectomy may not be candidates for immediate free-flap breast reconstruction because of medical comorbidities or postmastectomy radiation therapy. In this setting, flap reconstruction may be intentionally delayed or staged with tissue expander placement ("delayed-immediate" reconstruction). The optimal reconstructive choice and incidence of complications for these approaches remain unclear. Read More

View Article and Full-Text PDF

Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study.

Ann Hematol 2021 Jul 16. Epub 2021 Jul 16.

Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, 10700, Thailand.

The incidence and outcomes of aplastic anemia (AA) in Asia remain limited. This study aimed to explore the incidence and outcomes of patients with adult AA across the country of Thailand. This is a prospective multi-center nationwide population-based observational study of AA patients aged at least 15 years old, diagnosed from August 2014 to July 2016, with a longitudinal follow-up period over 2 years. Read More

View Article and Full-Text PDF

Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.

J Cancer Res Ther 2021 Jul;17(3):676-687

Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China; Sun Yat-Sen University Cancer Center, Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy; Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Purpose: The purpose of our meta-analysis is to clarify whether the biomarker of programmed cell death ligand-1 (PD-L1) could predict the treatment efficacy and prognosis of programmed cell death protein-1 (PD-1)/PD-L1 immune-checkpoint inhibitors (ICIs) in head and neck cancer (HNC) patients.

Materials And Methods: We performed the article search in four main online databases. The search deadline was September 8, 2020. Read More

View Article and Full-Text PDF

EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.

J Cancer Res Ther 2021 Jul;17(3):664-670

Department of Oncology, Affiliated Hospital of Chengde Medical College, Chengde, China.

Objective: The objective of this study was to perform a meta-analysis comparing the efficiency of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with chemotherapy to EGFR TKI treatment alone in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

Materials And Methods: Following keyword queries in databases and identification of randomized control trials for inclusion, hazard ratios (HRs), relative risks (RRs), and associated 95% confidence intervals (95% CIs) were determined.

Results: Ten randomized controlled trials involving 1354 participants with NSCLC were evaluated. Read More

View Article and Full-Text PDF

Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.

J BUON 2021 May-Jun;26(3):917-923

Department of Pharmacy, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China.

Purpose: To investigate the clinical efficacy and safety of apatinib combined with tegafur-gimeracil-oteracil potassium (S-1) in the second-line treatment of advanced gastric cancer.

Methods: A total of 126 patients with advanced gastric cancer admitted to our hospital from January 2017 to September 2018 were enrolled as the research objects, none of whom underwent surgery. For these patients, second-line treatment was recommended due to the failure of first-line treatment. Read More

View Article and Full-Text PDF

Two therapeutic regimens for advanced gastric carcinoma: DOS chemotherapy alone vs. trastuzumab combined with DOS.

J BUON 2021 May-Jun;26(3):904-910

Department of Gastroenterology, Zhuji Affiliated Hospital of Shaoxing University, Zhuji, China.

Purpose: The purpose of this study was to explore the efficacy and safety of trastuzumab combined with docetaxel, oxaliplatin and S-1 (DOS regimen) in neoadjuvant chemotherapy for advanced gastric carcinoma.

Methods: A total of 106 patients with advanced gastric carcinoma were divided into Trastuzumab + DOS group (n=53) and DOS group (n=53). The HER-2-positive patients were treated with trastuzumab combined with DOS regimen, while the HER-2-negative patients were treated with DOS regimen alone. Read More

View Article and Full-Text PDF